I N V E S T O R P R E S E N TAT I O N Q 4 2 0 1 6

TM

HEALTH THERAPEUTICS

E N H A N C IN G HE A LTH THRO U GH CANNABIS S CIENCE

WWW.EMERALD.CARE T S X . V: E M H
 DISCLAIMER
THE STATEMENTS MADE IN THIS PRESENTATION MAY INCLUDE FORWARD-LOOKING STATEMENTS THESE RISKS AND UNCERTAINTIES RELATE TO, AMONG OTHER THINGS, CHANGES IN LAWS,

REGARDING THE FUTURE OPERATIONS, OPPORTUNITIES OR FINANCIAL PERFORMANCE OF EMERALD REGULATIONS AND GUIDELINES RELATING TO MEDICAL MARIHUANA AND THE POSSIBLE LEGALIZATION

HEALTH THERAPEUTICS (THE COMPANY). FORWARD LOOKING STATEMENTS INCLUDE THE ESTIMATED OF MARIHUANA BY THE FEDERAL GOVERNMENT; CHANGES IN GOVERNMENT; CHANGES IN

INCREASE IN THE COMPANYS PRODUCTION SQUARE FOOTAGE; INCREASES IN THE COMPANYS GOVERNMENTAL POLICY; THE CONTINUED AVAILABILITY OF CAPITAL FINANCING AND GENERAL

PRODUCTION; THE LEGALIZATION OF RECREATIONAL MARIHUANA; THE SIZE OF THE MEDICAL ECONOMIC, MARKET OR BUSINESS CONDITIONS; RELIANCE ON MANAGEMENT; THE INABILITY OF THE

MARIHUANA MARKET AND THE RECREATIONAL MARIHUANA MARKET; THE COMPANYS EXPANSION COMPANY TO EXPAND ITS CURRENT FACILITY OR OBTAIN ADDITIONAL FACILITY SPACE; FAILURE TO

GOALS INCLUDING SCALABILITY, INCREASES IN SQUARE FOOTAGE, PRODUCTION AND REVENUE; THE OBTAIN APPROVAL BY HEALTH CANADA FOR THE COMPANY TO INCREASE PRODUCTION AND

COMPANYS POSITION IN THE MARIHUANA MARKET IN RESPECT OF DEMAND AND COMPETITION; THE PRODUCTION SQUARE FOOTAGE; UNFAVOURABLE PUBLICITY OR CONSUMER PERCEPTION OF THE

COMPANY BECOMING A LEADING BRAND IN CANNABIS-BASED PRODUCTS; AND THE COMPANYS NEAR MEDICAL MARIHUANA INDUSTRY; THE IMPACT OF ANY NEGATIVE SCIENTIFIC STUDIES ON THE EFFECTS

TO LONG TERM GOALS INCLUDING INCREASES IN PATIENT ACQUISITION, FACILITY EXPANSION, CLINICAL OF CANNABIS; THE GROWTH IN THE MEDICAL AND RECREATIONAL MARIHUANA MARKETS BEING LESS

TRIALS AND PRODUCT DEVELOPMENT AS WELL AS MARKET CAPTURE, REVENUE AND CONSOLIDATION THAN ANTICIPATED; INCREASED COMPETITION IN THE MARKET PLACE; THE COMPANYS ABILITY TO

OF THE MARIHUANA MARKET. MEET ITS NEAR AND LONG-TERM GOALS; AND THE COMPANYS ABILITY TO RETAIN A COMPETITIVE

ADVANTAGE IF MARIHUANA IS LEGALIZED AS WELL AS THE RISK FACTORS SET OUT IN THE COMPANYS

THESE FORWARD-LOOKING STATEMENTS ARE ONLY ESTIMATIONS BASED UPON THE INFORMATION ANNUAL INFORMATION FORM AND OTHER PUBLICLY FILED DISCLOSURE DOCUMENTS. UNDUE

AVAILABLE TO EMERALD HEALTH THERAPEUTICS, AS OF THE DATE OF THIS PRESENTATION. EXCEPT AS RELIANCE SHOULD NOT BE PLACED ON FORWARD LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF

REQUIRED BY LAW, WE EXPRESSLY DISCLAIM ANY RESPONSIBILITY TO PUBLICLY UPDATE OR REVISE THE DATE HEREOF.

OUR FORWARD-LOOKING STATEMENTS, WHETHER AS A RESULT OF NEW INFORMATION, FUTURE

EVENTS OR OTHERWISE. THUS, THE FORWARD-LOOKING STATEMENTS HEREIN INVOLVE KNOWN AND ALL FORWARD-LOOKING STATEMENTS CONTAINED HEREIN ARE QUALIFIED IN THEIR ENTIRETY BY THE

UNKNOWN RISKS AND UNCERTAINTIES SUCH THAT ACTUAL FUTURE OPERATIONS, OPPORTUNITIES OR FOREGOING CAUTIONARY STATEMENTS. RELIANCE SHOULD NOT BE PLACED ON FORWARD LOOKING

FINANCIAL PERFORMANCE MAY DIFFER MATERIALLY FROM THESE FORWARD-LOOKING STATEMENTS. STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE HEREOF.

WWW.EMERALD.CARE
2 / 18 | Q4 2016
 BIG 5
CANADIAN
CANNABIS
PU BCOS 2

DRIED & OILS LICE NSE DRIED & OILS

E ST. P RO D U CTI ON
100,000+ FT 2
SPA CE BY 2018 100,000+ FT 2
AV ER A GE VALU E

$52M MAR K E T C AP 1 $520M

AV ER A GE VALU E
1 As of November 14, 2016
2 Big 5 Cannabis Pubcos: CGC, APH, ACB, MT, OGI
WWW.EMERALD.CARE 3 / 18 | Q4 2016
 T R A N S FO R M AT I O N A L M I L E S TO N E S

LEGALIZATION

H1 2017 H2 2017 H1 2018 Recreational

Expansion Products & R&D Production Expanded Sales

WWW.EMERALD.CARE
4 / 18 | Q4 2016
 HIGH GROWTH POTENTIAL IN HIGH GROWTH SECTOR

LEGALIZATION

$200M 1
$5B
2

MEDICAL MARKET RECREATIONAL MARKET

1 Projected market based on Health Canada Market Statistics: http://www.hc-sc.gc.ca/dhp-mps/marihuana/info/market-marche-eng.php

2 Market value based on Deloitte LLP: Recreational Marijuana - Insights and opportunities - June 2016
WWW.EMERALD.CARE
5 / 18 | Q4 2016
 EHT HIGHLIGHTS

LEGALIZATION

PRODUCTION SCALABILITY MARKET REVENUE

SEED TO SALE E-COMMERCE
& CULTIVATION CAPTURE EXPANSION

Vertically Dried and oil Facility in Mass production Limited Initial market
integrated cannabis sales. Victoria, BC competition $5.6B
enterprise

CU R R E N T E XPANSIO N GOALS

WWW.EMERALD.CARE
6 / 18 | Q4 2016
 A DVA N C E D P RO D U CT S & B R A N D I N G

STRONG GENETIC DIVERSITY

CBX CBD THC:CBD THC THC+

> 3%
CBD
CBG, CBC, THC = CBD < 17% > 17%
THCV, CBDV THC THC

E M E RA L D R ANGE

CANNABIS O I L E A SY FOR CO NS U MERS

DRI E D CANNABI S
& PHY SICIANS

WWW.EMERALD.CARE
7 / 18 | Q4 2016
 E X P A N S I O N TA R G E T S LEGALIZATION

PHASE 1 PHASE 2 PHASE 3

50,000 FT2 100,000 FT2 1 million + FT2

5,000 KG 10,000 KG 100,000+ KG

production / year production / year production / year

$25M potential $50M potential $500M+ potential

sales* sales* sales*

*Potential sales based on sale price of $5/g

WWW.EMERALD.CARE
8 / 18 | Q4 2016
 L O W - C O S T A D V A N TA G E

FRIENDLY BC UTILITY AGRI-BUSINESS EXPERIENCED

CLIMATE ADVANTAGE TRACK RECORD LABOUR POOL

Optimal growing 3rd lowest Management with Leading team with

environment electricity cost in proven success in extensive history in
Canada scalable agriculture cannabis production

WWW.EMERALD.CARE
9 / 18 | Q4 2016
 '
TA R G E T P R O D U CT I O N V S D E M A N D (
0
$
LEGALIZATION 1
' &
2
& 0
' 2 3
( 0 (
& 3
2 0 7
& $ ( ,
2 0 7
& 3 1 2
2 0 ' , 1
SUPPLY

3 ( 2
0 ' 7
3 ( 1
7 ( ,
( ' 0 2
7 ( ,
' 2 $ 1
, 0 1
( 2 $ 1
0 '
1 1
$ '
1
' medical expansion recreational branding

CURRENT UPCOMING PHASE 1 PHASE 2 PHASE 3

WWW.EMERALD.CARE
10 / 18 | Q4 2016
 EXPERIENCED MANAGEMENT TEAM

Bin Huang, PhD, MBA Sandra Pratt, CPA, CA

President & CEO CFO

20+ years in life sciences including 20+ years in accounting & finance:
15 years as CEO Angiotech Pharmaceuticals

Traviss Graham Frey Garabagi, PhD

VP Production VP R&D and QAP

15+ years in cannabis production, 10+ years R&D in plant molecular

processing, and product development. genetics and medical technologies

WWW.EMERALD.CARE
11 / 18 | Q4 2016
 T H E E M E R A L D A D V A N TA G E

LEGALIZATION

KEY LEADERSHIP CLINICAL SUPERIOR

STAKEHOLDER EXPERIENCE TRIALS BRAND

Emerald Health Life sciences, drug Clinical expertise & Become the
Sciences development, clinical networks to expand leading brand in
testing, product patient base cannabis-based
approvals and products
distribution

WWW.EMERALD.CARE
12 / 18 | Q4 2016
 BOARD OF DIRECTORS

Avtar Dhillon, MD Jim Heppell, BSc, LLB

Chairman and former CEO of Director and former CEO of
Inovio Pharmaceuticals, Inc. Sophiris Bio Inc.

(NASDAQ:INO) and Board Member of (NASDAQ:SPHS) and previous President

several life sciences companies and Director of BC Advantage Funds

Bob Rai, BSc Punit Dhillon, BA

Chairman and CEO of CEO of Oncosec (NASDAQ:ONCS)
Canadian Pacific Global Pharmaceuticals
Former Vice President of Finance and
Director of Vanc Pharmaceutica Inc. Operations at Inovio Pharmaceuticals
(TSX:NPH) and 20+ years of pharmacy
experience

WWW.EMERALD.CARE
13 / 18 | Q4 2016
 MEMBERSHIP IN CANNABIS CANADA

EHB member of Cannabis Canada Association (CCA)

Avtar Dhillon Board Member

Bin Huang Company Representative
Maheep Dhillon Regulations Committee Member

CCA provides industry feedback and recommendations

in-person to Health Canada and Government

Active voice on regulatory changes,

patient advocacy and industry logistics
www.cann-can.ca

WWW.EMERALD.CARE
14 / 18 | Q4 2016
 MOVING FORWARD

N E AR TO M I D TO
MI D T E R M LO N G T E R M

Patient acquisition Legalization

Facility expansion Market capture

Clinical trials Mass revenue

Product development Consolidation

WWW.EMERALD.CARE
15 / 18 | Q4 2016
 CO M PA R A B L E S

Canopy Aphria Inc. Mettrum Aurora Organigram Supreme

Market Cap1 $1.29B $553M $274M $517M $327M $204M $52M

Fully Licensed

Scalability to
meet demand

Quarterly Expense2 $7.5M $3.0M $4.3M $1.5M $7.5M $2.0M $440K

Quarterly Revenue2 $7.0M $4.4M $4.2M $219K $894K $0 $100K

1 As at November 14, 2016

2 Figures based on most recently published interim financials for each company as at November 14, 2016
WWW.EMERALD.CARE
16 / 18 | Q4 2016
 INVESTMENT HIGHLIGHTS

TM

GROWTH SCALABILITY EXPERTISE

WWW.EMERALD.CARE
17 / 18 | Q4 2016
 THANK YOU!

TO L E A R N M O R E , P L E A S E C O N TA CT:

SANDY PRATT
CFO

T: + 1 8 O O 7 5 7 3 5 3 6
E: INVEST@EMERALD.CARE

WWW.EMERALD.CARE
18 / 18 | Q4 2016